Ticagrelor Market Research Report - Global Forecast till 2027

Global Ticagrelor Market: Information by Dosage (Mg) (90 MG and 60 MG), Route of Administration (Oral and Nasogastric Tube), Application (Acute Coronary Syndrome and Heart Surgeries (Angioplasty, Stent Placement and Coronary Artery Bypass Graft)) End User (Hospitals and Clinics and Ambulatory Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0324-CR | July 2019 | Region: Global | 101 pages

The Global Ticagrelor Market is expected to register a CAGR of 9.00% and is anticipated to reach USD 2554.39 Million by 2027.


Ticagrelor is an anti-platelet drug which decreases the platelet aggregation and prevents blood clots. Ticagrelor works by binding to the P2Y12 in a unique manner and inhibits the adenosine diphosphate (ADP) signaling by locking the receptor and makes it inactive. This hinders the platelet aggregation and reduces blood clots, thereby reducing the risk of acute coronary syndrome (ACS).


The increasing cardiovascular rate is eventually driving the growth of the ticagrelor market and rise in the older population has a direct effect on the ticagrelor market, as the older population is more prone to injuries and other health conditions, are the major drivers propelling market growth. However, Ticagrelor causes bleeding that can be serious and sometimes leads to death, constrain the growth of the market.


Market Dynamics


Cardiovascular disorders are heart conditions that include diseased vessels, structural problems, and blood clots. Ticagrelor drugs used in the treatment of cardiovascular disorders interfere with blood coagulation by inhibiting platelet aggregation. In acute coronary syndrome, the combination of ticagrelor and aspirin is reported to have reduced the prevalence of vascular deaths and myocardial infarctions more than the combination of clopidogrel and aspirin. For instance, according to the American Heart Association, in 2014, around 31% of the deaths in the US were due to cardiovascular disorders.


Similarly, as per the American Heart Association, approximately USD 555 billion was spent in the Americas for the treatment of cardiovascular disorders. Moreover, the increasing aging population is likely to positively affect market growth, thus spurring the demand for the ticagrelor market. Additionally, the increasing occurrences of obesity are expected to fuel the cardiovascular patient pool indirectly, thus encouraging the demand for the ticagrelor market. On the other hand, the high bleeding complications of ticagrelor is anticipated to hamper the market growth.


Global Ticagrelor Market Size, by End User, 2017 (USD Million)
 Ticagrelor Market


Source: MRFR Analysis


Segmentation


The global ticagrelor market has been segmented into dosage (Mg), route of administration, application, and end user. By dosage (Mg), the market has been segmented 90 mg and 60 mg. Based on the route of administration, the market has been segmented into the oral and nasogastric tube. Based on application, the market has been bifurcated into acute coronary syndrome and heart surgeries. Heart surgeries are further divided into angioplasty, stent placement, and coronary artery bypass graft. By end user, the market has been segmented into hospitals and clinics and ambulatory centers. The hospitals and clinics segment accounted for a market value of USD 522.03 million in 2017.


Key Players


The player in the global ticagrelor market is AstraZeneca, PLC.


Asia-Pacific Ticagrelor Market Share, by Country, 2017 (%)
 Ticagrelor Market


Source: MRFR Analysis


Regional Analysis


The global ticagrelor market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the global ticagrelor market during the forecast period. This is attributed to its sustainable growth in GDP per capita income and the rising geriatric population highly prone to degenerative diseases and chronic illnesses, which have caused an increased verge of diagnosis and therapeutics. The European market for ticagrelor is expected to be the second-largest during the forecast period. The rising patient population of strokes and cardiovascular disorders, increasing research on antiplatelets, availability of advanced treatment facilities, increasing healthcare expenditure, and introduction of advanced and integrated treatment options into the market along with the presence of good healthcare infrastructure is expected to boost the growth of the market in this region. Asia-Pacific is estimated to be the fastest-growing market due to the increasing per capita disposable incomes along with government initiatives to enhance the quality of healthcare. In addition to this, rising cardiovascular diseases being the primary concern in this region. Moreover, in the Asia-Pacific region, China accounted for a market share of 28.0% in 2017. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.


Key Updates


No recent critical developments regarding the market.


Market Segmentation


Global Ticagrelor Market, by Dosage (MG)



  • 90 Mg

  • 60 Mg


Global Ticagrelor Market, by Route of Administration



  • Oral

  • Nasogastric Tube


Global Ticagrelor Market, by Route of Application



  • Acute Coronary Syndrome

  • Heart Surgeries

  • Angioplasty

  • Stent Placement

  • Coronary Artery Bypass Graft


Global Ticagrelor Market, by End User



  • Hospitals & Clinics

  • Ambulatory Centers

  • Others


Global Ticagrelor Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Challenges in Global Ticagrelor Market


Intended Audience



  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies



Frequently Asked Questions (FAQ) :


Ticagrelor market projected to grow at approximately 9% CAGR during the assessment period (2018-2027).

The valuation of the global ticagrelor market is estimated to increase to USD 2554.39 MN by the end of 2027.

Large patient pool suffering from heart problems and increasing product development, commercialization, and improving funding for R&D by the market players are major tailwinds pushing the growth of the global ticagrelor market.

North America holds the largest share in the global ticagrelor market, followed by Europe and the Asia Pacific, respectively.

AstraZeneca, Eli Lilly, Boehringer, Ingelheim, Pfizer, Amgen, Merck, Roche, GSK, Boehringer, Alexion, and Amgen, are some of the top players operating in the global ticagrelor market.

Global Ticagrelor Market - Summary


Overview:


Ticagrelor is an oral drug which prevents blood clots and reduces the probability of stroke and heart attack in patients with heart disorders. It is commercialized under the names of Possia, Brilique, and Brilinta. The drug is an anti-platelet medication which got approval by the U.S. Food and Drug Administration (FDA) in 2011. Its applications have extended to treat sickle cell disease, percutaneous coronary intervention (PCI), and acute coronary syndrome (ACS).


The global ticagrelor market is expected to reach a valuation of USD 2,554.39 million by 2027. It can register a 9% CAGR over the forecast period (2018-2027) to reach the benchmark. Increasing prevalence of cardiovascular disorders in Europe and North America is likely to boost the demand for the drug. In addition, its success in clinical trials, high effectiveness over clopidogrel, and its approval in more than 100 countries can boost the market growth till 2027.


The expanding geriatric populace is another driver of the ticagrelor market. Prevalence of chronic diseases and their susceptibility to these due to low immunity levels can positively impact market growth. In addition, growth opportunities for the market exist due to demand for anti-platelet drugs in the treatment of sickle cell disease and transient ischemic disease.


Segmentation:


Dosages of the drug available in the ticagrelor market are 60 mg and 90 mg. The 90 mg segment accounted for a large market share and predicted to dominate till the end of the forecast period. Its primary use in the treatment of acute coronary syndrome (ACS) can be attributed to its success over its counterpart. On the other hand, the 60 mg segment can accrue significant revenue for the ticagrelor market owing to its indication in heart patients. This is supported by evidence unearthed in the Phase 3 PEGASUS-TIMI 54 study by AstraZeneca. The study showed heart patients having a reduced probability in deaths by cardiovascular disease when the drug is taken in combination with low-dose aspirin.


Two routes of administration described include oral and nasogastric tube. Oral segment has captured a large share of the ticagrelor market and will continue to be the dominant segment out of the two. But the nasogastric tube segment is likely to generate significant revenue owing to rising numbers of bedridden patients with dysphagia.


Applications of the drug include heart surgeries and acute coronary syndrome. Acute coronary syndrome can induce massive demand for the ticagrelor market owing to high prevalence of cardiac disorders. On the other hand, heart surgeries can induce the demand for the drug owing to its ability to prevent clots.


Market end-users include hospitals & clinics, ambulatory centers, and others. Hospitals & clinics are touted to be the primary end-users of ticagrelor owing to the healthcare institution being a trusted source of diagnosis and treatment of ACS. Anti-platelet drugs are known to prevent cardiac arrests and strokes in patients with PCI. On the other hand, ambulatory centers have experienced the efficacy of the drug which reduces the chances of ischemic heart attacks 24 hours after PCI on administration.


Regional Analysis:


Geographic segmentation of the ticagrelor market reveals details regarding Americas, Europe, Asia Pacific (APAC), and Rest-of-the-World (RoW).


The Americas is expected to dominate the market till the end of the forecast period owing to massive healthcare expenditure dedicated by the nations of the U.S. and Canada to curb mortality rates linked to cardiovascular diseases. Europe, on the other hand, is expected to assume the second position in ticagrelor market owing to investments in anti-platelet therapy treatments and high incidence of strokes and cardiovascular disorders. The APAC region has a wide ambit for the ticagrelor market owing to the large patient pool and supportive healthcare policies in Australia, India, and China.


Competitive Landscape:


The ticagrelor market is monopolistic in nature with a single player controlling its production and manufacture, AstraZeneca plc. It has decided to protect itself from patent infringement by preventing other drug manufacturers from creating generics. Development of the drug in clinical trials has proven successful with it being approved for treating medical conditions other than strokes.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

USD YEN EURO GBP INR
TABLE OF CONTENT

2.1 Definition 14

2.2 Scope of the Study 14

2.3 Research Objective 14

2.4 Assumptions & Limitations 14

2.4.1 Assumptions 14

2.4.2 Limitations 14

2.4.3 Market Structure 14

3.1 Primary Research Methodology 16

3.2 Secondary Research Methodology 18

3.3 Market Size Estimation 19

3.4 Forecast Model 19

4.1 Drivers 21

4.1.1 Rising Cardiovascular Disorders 21

4.1.2 Increasing Geriatric Population 22

4.2 Restraints 22

4.2.1 High Bleeding Complications 22

4.3 Opportunities 22

4.3.1 Exploring New Applications 22

5.1 Porter’s Five Forces Model 24

5.1.1 Bargaining Power of Suppliers 24

5.1.2 Bargaining Power of Buyers 25

5.1.3 Threat of New Entrants 25

5.1.4 Threat of Substitutes 25

5.1.5 Intensity of Rivalry 25

5.2 Value Chain Analysis 26

5.2.1 R&D 26

5.2.2 Manufacturing 26

5.2.3 Distribution & Sales 26

5.2.4 Post-Sales Monitoring 26

5.3 Demand & Supply: Gap Analysis 27

5.4 Pricing Analysis 27

5.5 Investment Opportunities 27

5.6 Macroeconomic Indicators 27

5.7 Pipeline Analysis 28

6.1 Introduction 30

6.2 90 MG 31

6.3 60 MG 31

7.1 Introduction 33

7.2 Oral 34

7.3 Nasogastric Tube 34

8.1 Introduction 36

8.2 Acute Coronary Syndrome 37

8.3 Heart Surgeries 37

8.3.1 Angioplasty 38

8.3.2 Stent Placement 38

8.3.3 Coronary Artery Bypass Graft 39

9.1 Introduction 41

9.2 Hospitals and Clinics 42

9.3 Ambulatory Centers 42

10.1 Introduction 44

10.2 Americas 46

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.2.1 North America 48

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.2.1.1 US 50

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.2.1.2 Canada 52

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.2.2 South America 54

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3 Europe 56

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1 Western Europe 58

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1.1 Germany 60

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1.2 UK 62

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1.3 France 63

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1.4 Italy 65

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1.5 Spain 67

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.1.6 Rest of Western Europe 68

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.3.2 Eastern Europe 70

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4 Asia-Pacific 72

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4.1 Japan 74

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4.2 China 76

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4.3 India 77

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4.4 Australia 79

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4.5 South Korea 81

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.4.6 Rest of Asia-Pacific 82

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.5 Rest of the World 85

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.5.1 Middle East 87

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.5.2 Africa 89

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

10.5.3 Other Countries 90

The Ticagrelor Market, by Route of Administration

The Ticagrelor Market, by Application

The Ticagrelor Market, by End User

12.1 AstraZeneca, PLC 96

12.1.1 Company Overview 96

12.1.2 Financial Overview 96

12.1.3 Products Offering 97

12.1.4 Key Developments 97

12.1.5 SWOT Analysis 97

12.1.6 Key Strategy 97

13.1 Discussion Blue Print 99

13.2 References 100

TABLE 1 PRIMARY INTERVIEWS 17

TABLE 2 PIPELINE PRODUCTS 28

TABLE 3 GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 30

TABLE 4 GLOBAL TICAGRELOR MARKET FOR 90 MG, BY REGION, 2015–2027 (USD MILLION) 31

TABLE 5 GLOBAL TICAGRELOR MARKET FOR 60 MG, BY REGION, 2015–2027 (USD MILLION) 31

TABLE 6 GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 33

TABLE 7 GLOBAL TICAGRELOR MARKET FOR ORAL, BY REGION, 2015–2027 (USD MILLION) 34

TABLE 8 GLOBAL TICAGRELOR MARKET FOR NASOGASTRIC TUBE, BY REGION, 2015–2027 (USD MILLION) 34

TABLE 9 GLOBAL TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 36

TABLE 10 GLOBAL TICAGRELOR MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2015–2027 (USD MILLION) 37

TABLE 11 GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 37

TABLE 12 GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY REGION 2015-2027 (USD MILLION) 38

TABLE 13 GLOBAL TICAGRELOR MARKET FOR ANGIOPLASTY, BY REGION, 2015–2027 (USD MILLION) 38

TABLE 14 GLOBAL TICAGRELOR MARKET FOR STENT PLACEMENT, BY REGION, 2015–2027 (USD MILLION) 38

TABLE 15 GLOBAL TICAGRELOR MARKET FOR CORONARY ARTERY BYPASS GRAFT-, BY REGION, 2015–2027 (USD MILLION) 39

TABLE 16 GLOBAL TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 41

TABLE 17 GLOBAL TICAGRELOR MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2027 (USD MILLION) 42

TABLE 18 GLOBAL TICAGRELOR MARKET FOR AMBULATORY CENTERS, BY REGION, 2015–2027 (USD MILLION) 42

TABLE 19 GLOBAL TICAGRELOR MARKET, BY REGION 2015-2027 (USD MILLION) 45

TABLE 20 AMERICAS TICAGRELOR MARKET, BY REGION 2015-2027 (USD MILLION) 46

TABLE 21 AMERICAS TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 46

TABLE 22 AMERICAS TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 47

TABLE 23 AMERICAS TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 47

TABLE 24 AMERICAS TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 47

TABLE 25 AMERICAS TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 48

TABLE 26 NORTH AMERICA TICAGRELOR MARKET, BY COUNTRY 2015-2027 (USD MILLION) 48

TABLE 27 NORTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 49

TABLE 28 NORTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 49

TABLE 29 NORTH AMERICA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 49

TABLE 30 NORTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 49

TABLE 31 NORTH AMERICA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 50

TABLE 32 US TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 50

TABLE 33 US TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 50

TABLE 34 US TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 51

TABLE 35 US TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 51

TABLE 36 US TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 51

TABLE 37 CANADA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 52

TABLE 38 CANADA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 52

TABLE 39 CANADA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 52

TABLE 40 CANADA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 53

TABLE 41 CANADA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 53

TABLE 42 SOUTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 54

TABLE 43 SOUTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 54

TABLE 44 SOUTH AMERICA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 54

TABLE 45 SOUTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 55

TABLE 46 SOUTH AMERICA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 55

TABLE 47 EUROPE TICAGRELOR MARKET, BY REGION 2015-2027 (USD MILLION) 56

TABLE 48 EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 56

TABLE 49 EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 57

TABLE 50 EUROPE TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 57

TABLE 51 EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 57

TABLE 52 EUROPE TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 58

TABLE 53 WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2015-2027 (USD MILLION) 58

TABLE 54 WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 59

TABLE 55 WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 59

TABLE 56 WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 59

TABLE 57 WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 59

TABLE 58 WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 60

TABLE 59 GERMANY TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 60

TABLE 60 GERMANY TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 60

TABLE 61 GERMANY TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 61

TABLE 62 GERMANY TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 61

TABLE 63 GERMANY TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 61

TABLE 64 UK TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 62

TABLE 65 UK TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 62

TABLE 66 UK TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 62

TABLE 67 UK TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 63

TABLE 68 UK TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 63

TABLE 69 FRANCE TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 63

TABLE 70 FRANCE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 64

TABLE 71 FRANCE TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 64

TABLE 72 FRANCE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 64

TABLE 73 FRANCE TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 65

TABLE 74 ITALY TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 65

TABLE 75 ITALY TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 65

TABLE 76 ITALY TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 66

TABLE 77 ITALY TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 66

TABLE 78 ITALY TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 66

TABLE 79 SPAIN TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 67

TABLE 80 SPAIN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 67

TABLE 81 SPAIN TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 67

TABLE 82 SPAIN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 68

TABLE 83 SPAIN TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 68

TABLE 84 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 68

TABLE 85 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 69

TABLE 86 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 69

TABLE 87 REST OF WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 69

TABLE 88 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 70

TABLE 89 EASTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 70

TABLE 90 EASTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 70

TABLE 91 EASTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 71

TABLE 92 EASTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 71

TABLE 93 EASTERN EUROPE TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 71

TABLE 94 ASIA-PACIFIC TICAGRELOR MARKET, BY COUNTRY 2015-2027 (USD MILLION) 72

TABLE 95 ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 72

TABLE 96 ASIA-PACIFIC TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 73

TABLE 97 ASIA-PACIFIC TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 73

TABLE 98 ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 73

TABLE 99 ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 74

TABLE 100 JAPAN TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 74

TABLE 101 JAPAN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 74

TABLE 102 JAPAN TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 75

TABLE 103 JAPAN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 75

TABLE 104 JAPAN TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 75

TABLE 105 CHINA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 76

TABLE 106 CHINA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 76

TABLE 107 CHINA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 76

TABLE 108 CHINA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 77

TABLE 109 CHINA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 77

TABLE 110 INDIA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 77

TABLE 111 INDIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 78

TABLE 112 INDIA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 78

TABLE 113 INDIA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 78

TABLE 114 INDIA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 79

TABLE 115 AUSTRALIA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 79

TABLE 116 AUSTRALIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 79

TABLE 117 AUSTRALIA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 80

TABLE 118 AUSTRALIA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 80

TABLE 119 AUSTRALIA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 80

TABLE 120 SOUTH KOREA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 81

TABLE 121 SOUTH KOREA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 81

TABLE 122 SOUTH KOREA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 81

TABLE 123 SOUTH KOREA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 82

TABLE 124 SOUTH KOREA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 82

TABLE 125 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 82

TABLE 126 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 83

TABLE 127 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 83

TABLE 128 REST OF ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 83

TABLE 129 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 84

TABLE 130 REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2015-2027 (USD MILLION) 85

TABLE 131 REST OF THE WORLDTICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 85

TABLE 132 REST OF THE WORLDTICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 86

TABLE 133 REST OF THE WORLDTICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 86

TABLE 134 REST OF THE WORLDTICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 86

TABLE 135 REST OF THE WORLDTICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 87

TABLE 136 MIDDLE EAST TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 87

TABLE 137 MIDDLE EAST TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 87

TABLE 138 MIDDLE EAST TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 88

TABLE 139 MIDDLE EAST TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 88

TABLE 140 MIDDLE EAST TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 88

TABLE 141 AFRICA TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 89

TABLE 142 AFRICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 89

TABLE 143 AFRICA TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 89

TABLE 144 AFRICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 90

TABLE 145 AFRICA TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 90

TABLE 146 OTHER COUNTRIES TICAGRELOR MARKET, BY DOSAGE (MG) 2015-2027 (USD MILLION) 90

TABLE 147 OTHER COUNTRIES TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION) 91

TABLE 148 OTHER COUNTRIES TICAGRELOR MARKET, BY APPLICATION 2015-2027 (USD MILLION) 91

TABLE 149 OTHER COUNTRIES TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2015-2027 (USD MILLION) 91

TABLE 150 OTHER COUNTRIES TICAGRELOR MARKET, BY END-USER 2015-2027 (USD MILLION) 92

FIGURE 1 TOP-DOWN & BOTTOM-UP APPROACHES 19

FIGURE 2 MARKET DYNAMICS: GLOBAL TICAGRELOR MARKET 21

FIGURE 3 PORTER’S FIVE FORCES ANALYSIS: GLOBAL TICAGRELOR MARKET 24

FIGURE 4 VALUE CHAIN ANALYSIS OF THE GLOBAL TICAGRELOR MARKET 26

FIGURE 5 GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2017 & 2027 (USD MILLION) 30

FIGURE 6 GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2017 & 2027 (USD MILLION) 33

FIGURE 7 GLOBAL TICAGRELOR MARKET, BY APPLICATION 2017 & 2027 (USD MILLION) 36

FIGURE 8 GLOBAL TICAGRELOR MARKET, FOR HEART SURGERIES BY TYPE 2017 & 2027 (USD MILLION) 37

FIGURE 9 GLOBAL TICAGRELOR MARKET, BY END-USER 2017 & 2027 (USD MILLION) 41

FIGURE 10 GLOBAL TICAGRELOR MARKET, BY REGION 2017 & 2027 (USD MILLION) 45

FIGURE 11 AMERICAS TICAGRELOR MARKET SHARE, BY REGION 2017 (%) 46

FIGURE 12 AMERICAS TICAGRELOR MARKET SHARE, BY COUNTRY 2017 (%) 48

FIGURE 13 EUROPE TICAGRELOR MARKET, BY REGION 2017 (%) 56

FIGURE 14 WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2017 (%) 58

FIGURE 15 ASIA-PACIFIC TICAGRELOR MARKET, BY COUNTRY 2017 (%) 72

FIGURE 16 REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2017(%) 85

Company Landscape


Introduction


AstraZeneca is the sole manufacturer of Brilinta (generic: ticagrelor) an “anti-platelet” medication that helps prevent stroke or serious heart problems in patients who have had a heart attack or severe chest pain (angina). The drug works by preventing platelets in the blood from sticking together and forming a blood clot. Brilinta by AstraZeneca was approved by the US Food & Drug Administration (FDA) in July 2011.


The Brilinta 90 mg dosage form by AstraZeneca has been approved in over 100 countries and is included in 12 major acute coronary syndrome (ACS) treatment guidelines globally. Additionally, Brilinta 60mg is approved in over 60 countries for the long-term prevention of death from cardiovascular diseases, heart attack, and stroke for patients with a history of heart attack. AstraZeneca is strongly engaged in growth strategies in order to promote its product across the globe. For instance, in June 2017, the China Food and Drug Administration (CFDA) approved Brilinta 60 mg tablets for patients with a history of heart attack. Subsequently, in July 2017, the Ministry of Human Resources and Social Security agreed to add Brilinta 90 mg to the National Reimbursable Drugs List (NRDL). Similarly, in August 2017, AstraZeneca presented Phase III trial data (PEGASUS-TIMI 54) at the Annual Congress of the European Society of Cardiology (ESC) in Barcelona, Spain. These approvals and presentations are paving a way for the positive growth for Brilinta all over the globe.


The firm has also been focusing on diversifying the applications of Brilinta. For instance, the application of Brilinta in the prevention of vaso-occlusive crises in pediatric patients with sickle cell disease is under investigation. Additionally, the use of Brilinta in patients with type 2 diabetes and coronary artery disease without a previous history of myocardial infarction (MI) or stroke is also been studied. These wide applications of Brilinta are driving the growth of the ticagrelor market.


AstraZeneca has so far been the only provider of ticagrelor and has been accused of prolonging monopoly of the product beyond its legitimate patent life. The firm has been trying to withhold its market presence in the antiplatelet segment by applying for multiple patents. AstraZeneca has filed various lawsuits against firms that have been trying to enter the ticagrelor market by manufacturing generics of Brilinta. For instance, AstraZeneca has filed a lawsuit in the Delhi High Court against the Indian drug maker, Dr. Reddy’s Laboratories to block it from launching generic versions of Brilinta, AstraZeneca’s blockbuster medicine for heart ailments. Additionally, AstraZeneca filed similar lawsuits against Natco Pharmaceuticals and Micro Labs in the early months of 2018 and has blocked both the companies from launching copies of Brilinta.